Sanofi Investing €700 Million Ahead Of Launches
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi is ramping up for several product launches in the next 12 months, including a next-generation basal insulin Toujeo, Lemtrada for multiple sclerosis, Cerdelga for Gaucher’s disease and Praluent for high cholesterol.
You may also be interested in...
High Valuations Sideline Sanofi From The M&A Game…For Now
Sanofi CEO Chris Viehbacher said the company is focusing mainly on bolt-on acquisitions because valuations for targets have ballooned so significantly. Inversion deals are further inflating assets, he said.
Sanofi/Regeneron’s PCSK9 Inhibitor Gets Reassuring CV Data – And A Priority Review Voucher
Alirocumab was associated with lower rate of major cardiovascular events compared to placebo in post-hoc, interim Phase III analysis – boosting chances for FDA approval in 2015. The firm is taking no chances on review period, purchasing a priority review voucher from BioMarin.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.